---
title: "Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Safety questions"
description: "Safety questions on Xarelto (rivaroxaban) in nonvalvular atrial fibrillation, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: What happens if Xarelto is stopped early in atrial fibrillation? What are the most common side effects of Xarelto in atrial fibrillation? 2 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban) in nonvalvular atrial fibrillation: Safety questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)

Safety questions that apply to every indication of Xarelto are on [Xarelto (rivaroxaban), all indications: Safety](https://www.evicenter.com/medical-information/xarelto/safety).

## Warnings

<a id="xarelto-stopping"></a>

### What happens if Xarelto is stopped early in atrial fibrillation?

> “Premature discontinuation of any oral anticoagulant, including XARELTO, in the 
> absence of adequate alternative anticoagulation increases the risk of thrombotic 
> events. An increased rate of stroke was observed during the transition from 
> XARELTO to warfarin in clinical trials in atrial fibrillation patients. If XARELTO is 
> discontinued for a reason other than pathological bleeding or completion of a 
> course of therapy, consider coverage with another anticoagulant [see Dosage 
> and Administration (2.3, 2.4) and Clinical Studies (14.1)].”

Source: [XARELTO: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=6)

> “The protocol for ROCKET AF did not stipulate anticoagulation after study drug 
> discontinuation, but warfarin patients who completed the study were generally 
> maintained on warfarin. XARELTO patients were generally switched to warfarin 
> without a period of coadministration of warfarin and XARELTO, so that they 
> were not adequately anticoagulated after stopping XARELTO until attaining a 
> therapeutic INR. During the 28 days following the end of the study, there 
> were 22 strokes in the 4637 patients taking XARELTO vs. 6 in the 4691 patients 
> taking warfarin.”

Source: [XARELTO: Prescribing information, page 15, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=15)

## Side effects

<a id="xarelto-side-effects"></a>

### What are the most common side effects of Xarelto in atrial fibrillation?

> “The most common adverse reactions with XARELTO were bleeding complications 
> [see Warnings and Precautions (5.2)].”

Source: [XARELTO: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=7)

> “In the ROCKET AF trial, the most frequent adverse reactions associated with 
> permanent drug discontinuation were bleeding events, with incidence rates of 
> 4.3% for XARELTO vs. 3.1% for warfarin. The incidence of discontinuations for 
> non-bleeding adverse events was similar in both treatment groups.”

Source: [XARELTO: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=7)

Note: The first passage covers adult patients in all approved indications; the second is specific to ROCKET AF, which compared XARELTO with warfarin in adults with nonvalvular atrial fibrillation. See the ROCKET AF bleeding question for the bleeding rates.

## Related pages
- [Medical information: Xarelto (rivaroxaban): Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)
- [Indication](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation/guidelines)
